Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with atopic dermatitis (AD) as defined by the Hanifin and Rajka criteria.~* Participants with a history of AD for at least 2 years.~* Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at screening and baseline.~* Participants with body surface area (BSA) of AD involvement, excluding the face and intertriginous areas, of 3% to 20% at screening and baseline.~* Participants who agree to discontinue all agents used to treat AD from screening through the final follow-up visit.~Exclusion Criteria:~* Participants with evidence of active acute or chronic infections.~* Use of topical treatments for AD (other than bland emollients) within 2 weeks of baseline.~* Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine) within 4 weeks or 5 half-lives of baseline (whichever is longer).~* Participants with other dermatologic disease besides AD whose presence or treatments could complicate the assessment of disease (eg, psoriasis).~* Participants with a history of other diseases besides dermatologic disorders (eg, other autoimmune diseases) taking treatments that could complicate assessments.~* Participants with cytopenias at screening, defined as:~  * Leukocytes \< 3.0 × 10\^9/L.~ * Neutrophils \< lower limit of normal.~ * Hemoglobin \< 10 g/dL.~ * Lymphocytes \< 0.8 × 10\^9/L~ * Platelets \< 100 × 10\^9/L.~* Participants with severely impaired liver function (Child-Pugh Class C) or end-stage renal disease (ESRD) on dialysis or at least 1 of the following:~  * Serum creatinine \> 1.5 mg/dL.~ * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 × upper limit of normal.~* Participants taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit (topical agents with limited systemic availability are permitted).~* Participants who have previously received Janus kinase (JAK) inhibitors, systemic or topical (e.g., ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Double Blind (DB): Vehicle BID (Type: PLACEBO_COMPARATOR): Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
- DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID (Type: ACTIVE_COMPARATOR): Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
- DB: Ruxolitinib 0.15% Once Daily (QD) (Type: EXPERIMENTAL): Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
- DB: Ruxolitinib 0.5% QD (Type: EXPERIMENTAL): Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
- DB: Ruxolitinib 1.5% QD (Type: EXPERIMENTAL): Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
- DB: Ruxolitinib 1.5% BID (Type: EXPERIMENTAL): Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
- Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID (Type: PLACEBO_COMPARATOR): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
- OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID (Type: ACTIVE_COMPARATOR): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
- OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID (Type: EXPERIMENTAL): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
- OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID (Type: EXPERIMENTAL): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
- OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID (Type: EXPERIMENTAL): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
- OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID (Type: EXPERIMENTAL): Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).